PDCD1 and glioblastoma: It is not expected that the therapeutic effects of immunotherapies would rely mainly on the reinvigoration of TILs, as ex vivo treatment with anti–PD-1 therapy shows limited reinvigoration of terminally differentiated CD8+ T cells isolated from human GBM (89).